ReviewFrontiers in oncology2024
Keap1-Nrf2 pathway: a key mechanism in the occurrence and development of cancer.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 53 citations in OpenAlex.
- LC-MS/MS-based peptide identification, molecular simulations, and biological validation for targeted discovery of antioxidant peptides from large yellow croaker.Food chemistry: X · 2026Article
- Tetramethylpyrazine modulates the Nrf2/JNK axis to intervene in ferroptosis and neuroinflammation after spinal cord injury: an integrated perspective from antioxidant to regenerative therapy.Molecular biology reports · 2026Review
- Green-Synthesized Silver Nanoparticles fromAntioxidants (Basel, Switzerland) · 2026Article
- Methotrexate Alters Nrf2/HO-1 Protein Expression and Intrinsic Apoptosis-Associated Protein Responses in OVCAR-3 Ovarian Cancer Cells: Differential Modulation by Antioxidant Compounds.Journal of biochemical and molecular toxicology · 2026Article
- FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting.Antioxidants (Basel, Switzerland) · 2026Review
- Honeycomb Enhances the Egg-Laying Capacity of Laying Hens by Modulating Ovarian Function and Yolk Precursor Synthesis.Animals : an open access journal from MDPI · 2026Article
- Exercise-Driven NRF2 Activation as a Systemic Neuroprotective Strategy: Integrating Redox Biology, Muscle-Brain Crosstalk, and Therapeutic Targeting in Neurodegeneration.Biochemical genetics · 2026Review
- Shenling Baizhu powder reduced the oxidative stress and mitochondrial damage during ulcerative colitisthe Kelch-like ECH-associated protein 1-NF-E2-related factor 2/nuclear factor kappa B pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
- Dietary Antioxidants and Redox Signaling in Cancer Prevention: Mechanistic Insights and Metabolic Inflammation.Nutrients · 2026Review
- Vitexin inhibits renal cell carcinoma progression by targeting Galectin-1-mediated glycolytic metabolism.Molecular biology reports · 2026Article
- AI-Driven Combination Therapy for Counteracting Dysregulated Genes in Lung Adenocarcinoma: Contribution-Aware Metaheuristic for Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cutibacterium acnes-Derived Extracellular Vesicles Promote Epithelial Ovarian Cancer Progression by Activating the KEAP1-NRF2 Antioxidant Pathway to Suppress Ferroptosis.Microbial biotechnology · 2026Article
- Integrated Proteomics and Metabolomics Analyses Reveal That Phosphatidylethanolamine Reprograms Macrophage Immunometabolism and Attenuates LPS-Driven Inflammation.Journal of proteome research · 2026Article
- The role of NRF2 in human cancers: Pre-clinical insights paving the way for clinical trials.Journal of pharmaceutical analysis · 2026Review
- Pyrimethamine Restores KEAP1-Mediated Degradation of Select NRF2 Mutants in Esophageal Squamous Cell Carcinoma.Cancers · 2026Article
- ST3GAL1 drives colorectal cancer metastasis by mediating NRF2-induced activation of the integrin-α6β4 signaling pathway via sialylation modification.Journal of translational medicine · 2026Article
- Reactive oxygen species in health and disease.Molecular biomedicine · 2026Review
- NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts.Cancer chemotherapy and pharmacology · 2026Article
- Nuclear factor erythroid 2-related factor: potential use as a therapeutic strategy for viral infections.Archives of microbiology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Keap1-Nrf2 signaling pathway is a major regulator of the cytoprotective response, participating in endogenous and exogenous stress caused by ROS (reactive oxygen species). Nrf2 is the core of this pathway. We summarized the literature on Keap1-Nrf2 signaling pathway and summarized the following three aspects: structure, function pathway, and cancer and clinical application status. This signaling pathway is similar to a double-edged sword: on the one hand, Nrf2 activity can protect cells from oxidative and electrophilic stress; on the other hand, increasing Nrf2 activity can enhance the survival and proliferation of cancer cells. Notably, oxidative stress is also considered a marker of cancer in humans. Keap1-Nrf2 signaling pathway, as a typical antioxidant stress pathway, is abnormal in a variety of human malignant tumor diseases (such as lung cancer, liver cancer, and thyroid cancer). In recent years, research on the Keap1-Nrf2 signaling pathway has become increasingly in-depth and detailed. Therefore, it is of great significance for cancer prevention and treatment to explore the molecular mechanism of the occurrence and development of this pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.